Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state

Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state

Item
http://www.wikidata.org/entity/Q34510726
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionHumanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Lack of a significant drug interaction between raltegravir and tenofovir.Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal ImpairmentNucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
P2860

Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state

Item
http://www.wikidata.org/entity/Q34510726
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacokinetics of tenofovir ...... in combination at steady state
@ast
Pharmacokinetics of tenofovir ...... in combination at steady state
@en
Pharmacokinetics of tenofovir ...... in combination at steady state
@nl
type
label
Pharmacokinetics of tenofovir ...... in combination at steady state
@ast
Pharmacokinetics of tenofovir ...... in combination at steady state
@en
Pharmacokinetics of tenofovir ...... in combination at steady state
@nl
prefLabel
Pharmacokinetics of tenofovir ...... in combination at steady state
@ast
Pharmacokinetics of tenofovir ...... in combination at steady state
@en
Pharmacokinetics of tenofovir ...... in combination at steady state
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Pharmacokinetics of tenofovir ...... in combination at steady state
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.50.4.1304-1310.2006
P407
P433
P478
P577
P5875
P698
P932